Table 1.
Patient Demographics (n=51)
| Study Group Lymphedema | Control Group Lymphedema-Free | p-value | |
|---|---|---|---|
| Sex, female, n (%) | 25 (100) | 26 (100) | 1.000 |
| Age, years, mean±SD | 60.6±8.6 | 56.8±10.4 | 0.081 |
| Etiology, cancer type, n (%) | 0.002 | ||
| Cervical | 9 (36.0) | 0 (0.0) | |
| Endometrial | 11 (44.0) | 14 (53.8) | |
| Ovarian | 4 (16.0) | 12 (46.2) | |
| Vulvar | 1 (4.0) | 0 (0.0) | |
| ISL Stage (0-I/II–III), n (%) | 2(8.0)/23(92.0) | n/a | n/a |
| BMI, kg/m2, mean±SD | 25.6±4.9 | 25.3±4.6 | 0.840 |
| DM, n (%) | 6 (24.0) | 5 (19.2) | 0.941 |
| HTN, n (%) | 7 (28.0) | 7 (26.9) | >0.999 |
| Affected limb (Left/Right), n (%) | 14 (56.0)/11 (44.0) | n/a | n/a |
| Chemotherapy, n (%) | 9 (36.0) | 12 (46.2) | 0.651 |
| Radiotherapy, n (%) | 11 (44.0) | 2 (7.7) | 0.008 |
| Duration of post-cancer treatment follow-up, months, median [IQR] | 106.0 [42.0, 226.0] | 76.5 [66.0, 102.0] | 0.423 |
| Duration of LE, year, median [IQR] | 1.40 [0.55, 7.24] | n/a | n/a |
Notes: Normally distributed data are expressed as mean ± SD (standard deviation); non-normally distributed data are expressed as median [Inter-Quartile Range (IQR), 25–75%].
Abbreviations: ISL, International Lymphology Society; BMI, body mass index; DM, diabetes mellitus; HTN, hypertension; LE, lymphedema; n/a, not applicable.